Carcinoid somatostatinoma of the duodenum

Abstract

8. Rosenberg SA, Lotze MT, Muul LM, et al. Observation on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N EngZJMed 1985,313,1485-1492. Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokineactivated killer cells and interleukin-2 or high dose interleukin-2 alone. N EnglJ Med 1987,316,889-897. Ishikawa T, Imawari M, Moriyama T, et al. Immunotherapy of hepatocellular carcinoma with autologous lymphokine-activated killer cells and/or recombinant interleukin-2.y Cancer Res Clin Oncol 1988,114,283-290. Okuno K, Takagi H, Nakamura T, Nakamura Y, Iwasa Z, Yasutomi M. Treatment for unresectable hepatoma via selective hepatic infusion of lymphokine-activated killer cells generated from autologous spleen cells. Cancer 1986,58,1001-1006. Ettinghausen SE, Rosenberg SA. Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimizations of the schedule and route of administration of recombinant interleukin-2. Cancer Res 1986,&i, 2784-2792. Eberlein TJ, Rosenstein M, Spiess I’, Wesley R, Rosenberg SA. Adoptive chemoimmunotherapy of a syngeneic murine lymphoma with long-term lymphoid cell lines expanded in T cell growth factor. Cancer Immunol Immunother 1982,13,5-13. North RJ. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells.3 Exp Med 1982,155,1063-1074. West WH, Tauer KW, Yannelli JR, eral. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N EnglJ Med 1987,316,895-905.